Key result
TAVR for severe aortic stenosis yields comparable 1-year mortality across bicuspid and tricuspid anatomies.
Why the study?
Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis are scarce.
Cohort (n=1,272)
No
Supports TAVR consideration in bicuspid aortic stenosis; leaves open need for randomized confirmation of outcomes by anatomy.
BACKGROUND: Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. The study aims to compare the outcomes of transcatheter aortic valve replacement for AS in patients with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy. METHODS: We enrolled consecutive patients undergoing transcatheter aortic valve replacement for severe AS between 2012 and 2022 in this single-center retrospective cohort study. The primary outcome was mortality, while secondary outcomes included in-hospital complications such as stroke and pacemaker implantation and transcatheter heart valve hemodynamic performance. RESULTS: The number of patients with AS with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy was 328, 302, and 642, respectively. Self-expanding transcatheter heart valves were used in the majority of patients (n=1160; 91.4%). In the matched population, differences in mortality (30 days: 4.2% versus 1.7% versus 1.7%, P overall =0.522; 1 year: 10% versus 2.3% versus 6.2%, P overall =0.099) and all stroke (30 days: 1.0% versus 0.9% versus 0.0%, P overall =0.765; 1 year: 1.4% versus 1.6% versus 1.3%, P overall =NS) were nonsignificant, and the incidence of overall in-hospital complications was comparable among groups. Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44]; P =0.035). The proportion of patients with a mean residual gradient ≥20 mm Hg was the highest in those with type 0 bicuspid anatomy, although the need for permanent pacemaker implantation was the lowest in this group. CONCLUSIONS: Major clinical outcomes of transcatheter aortic valve replacement for AS in patients with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy are equivalent at short- and mid-term follow-up. These observations merit further exploration in prospective international registries and randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
He et al. (2023) conducted a cohort in severe aortic stenosis (n=1,272). Transcatheter aortic valve replacement vs. Type 0 bicuspid vs type 1 bicuspid vs tricuspid anatomy was evaluated on mortality (p=0.099). Transcatheter aortic valve replacement for severe aortic stenosis yielded comparable 1-year mortality across type 0 bicuspid (10%), type 1 bicuspid (2.3%), and tricuspid (6.2%) anatomies (P=0.099).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: